Abstract Library

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lunberg-Adams M

Authors: Lunberg-Adams M, James A, Perros P,

Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,

#594 Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors

Introduction: Recent European investigations demonstrated that persistently elevated (> 50 pg/ml) plasma neurokinin A (NKA) levels are associated with poor short-term survival in patients with midgut neuroendocrine tumors (NETS).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Diebold A, Boudreaux J, Wang Y, Anthony L, Uhlhorn A,

Keywords: midgut, neuroendocrine tumors (NETs), Neurokinin A (NKA), survival,